Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) released its quarterly earnings data on Monday. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02, Zacks reports. The company had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million.
Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.9%
Shares of SGIOY traded down $0.08 during mid-day trading on Thursday, reaching $8.35. The company's stock had a trading volume of 87,613 shares, compared to its average volume of 106,036. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $6.53 and a 12-month high of $8.99. The stock has a market cap of $14.20 billion, a PE ratio of 14.30, a price-to-earnings-growth ratio of 1.91 and a beta of 0.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13. The company's 50 day moving average is $8.48 and its 200 day moving average is $7.92.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Featured Articles
Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.
While Shionogi & Co., Ltd. Unsponsored ADR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
